Lonza Group (LZAGY) Stock Price, News & Analysis

Company Overview

Lonza Group AG is a Swiss contract development and manufacturing organization (CDMO) serving the pharmaceutical, biotechnology and healthcare industries. The company supports customers across the product life cycle, from early-stage development and clinical supply through commercial manufacturing and related regulatory services.

Lonza’s activities include the development and production of biologic medicines, small-molecule pharmaceuticals, active pharmaceutical ingredients, drug products, and specialized therapies. It also provides services for cell and gene therapies, including manufacturing technologies and supporting development capabilities. Lonza operates manufacturing, research and development, and service facilities across North America, Europe and Asia.

Founded in Switzerland in 1897, Lonza evolved from a chemicals and industrial company into a global provider focused primarily on pharmaceutical and biotechnology manufacturing. The company is headquartered in Basel, Switzerland. Wolfgang Wienand has served as chief executive officer since 2024, while Albert M. Baehny is chairman of the board.

Key Stats

• Today's Range: $67.82 to $69.13
• 50-Day Range: $65.06 to $74.21
• 52-Week Range: $58.53 to $74.36
• Volume: 73,342 shs
• Average Volume: 48,626 shs
• Market Capitalization: $48.55 billion
• P/E Ratio: N/A
• Dividend Yield: 0.20%
• Price Target: N/A
• Consensus Rating: Moderate Buy

Lonza Group Stock Analysis - MarketRank™

Lonza Group scored higher than 46% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Lonza Group has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Lonza Group has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 21.78%

Earnings Growth

Earnings for Lonza Group are expected to grow by 21.78% in the coming year, from $2.25 to $2.74 per share.

Price to Earnings Growth Ratio

Lonza Group has a PEG Ratio of 1.29. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Lonza Group has a P/B Ratio of 4.38. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of Lonza Group has been sold short.

Short Interest Ratio / Days to Cover

Lonza Group has a short interest ratio ("days to cover") of 0.42, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lonza Group has recently decreased by 64.05%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.8 / 5
• Dividend Strength: Weak

Dividend Yield

Lonza Group has a dividend yield of 0.21%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Lonza Group does not have a long track record of dividend growth.

Dividend Sustainability

Based on earnings estimates, Lonza Group will have a dividend payout ratio of 5.11% next year. This indicates that Lonza Group will be able to sustain or increase its dividend.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: N/A

News Sentiment

Lonza Group has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Lonza Group this week, compared to 0 articles on an average week.

MarketBeat Follows

1 people have added Lonza Group to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Lonza Group insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.07% of the stock of Lonza Group is held by insiders.

Percentage Held by Institutions

0.04% of the stock of Lonza Group is held by institutions.

Company Calendar

• Today: 9/28/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:LZAGY
• CIK: 1446711
• Web: www.lonza.com
• Phone: (161) 316-8111
• Fax: 41-61-316-9111
• Employees: 18,686
• Year Founded: 1897

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 30.72
• P/E Growth: 1.29
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.42
• Current Ratio: 2.24
• Quick Ratio: 1.77

Sales & Book Value

• Annual Sales: $7.88 billion
• Price / Sales: 6.16
• Cash Flow: $1.99 per share
• Price / Cash Flow: 34.79
• Book Value: $15.79 per share
• Price / Book: 4.38

Miscellaneous

• Outstanding Shares: 702,290,000
• Free Float: 701,798,000
• Market Cap: $48.55 billion
• Optionable: Not Optionable
• Beta: 1.09